Welcome to our dedicated page for Dyne Therapeutics SEC filings (Ticker: DYN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Dyne Therapeutics, Inc. filings document regulatory disclosures for a clinical-stage neuromuscular disease company advancing FORCE platform programs. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary cash-resource disclosures, investor presentation materials, clinical and FDA-related updates, and other business highlights tied to Duchenne muscular dystrophy and myotonic dystrophy type 1 programs.
The company’s definitive proxy materials cover board structure, director elections, executive compensation, equity awards, stockholder voting matters and governance practices. Other filings address board appointments, non-employee director compensation arrangements and Nasdaq-related inducement equity awards.
Dyne Therapeutics announced completion of enrollment in the registrational expansion cohort of its Phase 1/2 ACHIEVE trial of z‑basivarsen for myotonic dystrophy type 1. The cohort includes 71 participants, providing the main data set to support potential regulatory submissions.
The company plans topline data from this cohort in the first quarter of 2027, aiming to use these results, along with multiple ascending dose and long‑term extension data, for a potential Biologics License Application seeking U.S. Accelerated Approval in the third quarter of 2027. Dyne anticipates a potential U.S. launch in the first half of 2028 if Priority Review is granted and approval is received, and it is also pursuing approval pathways outside the U.S.
Dyne Therapeutics director Brian S. Posner bought additional shares of the company. On this Form 4, he reported an open-market purchase of 2,000 shares of Common Stock at a price of $18.21 per share on May 26, 2026. After this transaction, he directly owns 20,000 shares.
Dyne Therapeutics, Inc. director Brian S. Posner reported an open-market purchase of 2,500 shares of Common Stock on May 20, 2026 at $17.12 per share. Following this transaction, he directly owns a total of 18,000 Dyne Therapeutics shares.
Dyne Therapeutics Inc ownership disclosure: Janus Henderson Group plc reports beneficial ownership of 13,647,376 shares of Dyne common stock, representing 8.3% of the class. The filing states the Asset Managers exercise shared voting and shared dispositive power over these shares. The filing is submitted on behalf of Janus Henderson Group plc and describes that the Managed Portfolios hold the securities and have the right to receive dividends and sale proceeds.
T. Rowe Price Investment Management, Inc. amended its Schedule 13G to report beneficial ownership of 30,785,801 shares of Dyne Therapeutics common stock as of 03/31/2026. The filing shows sole voting power of 30,419,012 shares and a 18.7% ownership stake.
The filing is signed by Ellen York, Vice President, on 05/15/2026. The filer includes a statement denying beneficial ownership in the filing language.
Dyne Therapeutics, Inc. Chief Commercial Officer Johanna Friedl-Naderer reported an automatic sale of 228 shares of common stock on May 13, 2026 at a weighted average price of $18.36 per share. The shares were sold solely to cover tax withholding tied to the vesting of restricted stock units under a pre-arranged agreement treated as a binding contract consistent with Rule 10b5-1, meaning it was not a discretionary trade. After the transaction, she holds 154,353 shares in total, including 126,040 unvested restricted stock units.
Dyne Therapeutics, Inc. Chief Medical Officer Douglas Kerr reported an automatic sale of 1,564 shares of common stock. The shares were sold on May 13, 2026 at a weighted average price of $18.36 per share in multiple trades between $18.20 and $18.41.
The filing explains that these shares were automatically sold to satisfy tax withholding obligations related to the vesting of restricted stock units granted on February 12, 2026, under a restricted stock unit agreement described as a binding contract consistent with the affirmative defense under Rule 10b5-1. After this transaction, Kerr directly holds 170,042 shares of Dyne Therapeutics common stock, including 148,313 unvested restricted stock units.
Dyne Therapeutics, Inc. Chief Financial Officer Erick Lucera reported an automatic sale of 1,448 shares of common stock. The shares were sold in the open market at a weighted average price of $18.36 per share, within a range of $18.20 to $18.41.
According to the disclosure, this sale was automatically executed to cover tax withholding obligations tied to the vesting of restricted stock units granted on February 12, 2026, under a restricted stock unit agreement characterized as a binding contract consistent with the affirmative defense under Rule 10b5-1. Following the transaction, Lucera holds 123,925 shares directly, including 110,513 unvested restricted stock units.
Dyne Therapeutics CEO John Cox reported an automatic tax-related sale of 3,311 shares of common stock. The shares were sold on May 13, 2026 at a weighted average price of $18.36 per share to satisfy tax withholding obligations tied to the vesting of restricted stock units granted on February 12, 2026.
The sale was executed under a restricted stock unit agreement described as a binding contract consistent with the Rule 10b5-1 affirmative defense, meaning it was not a discretionary trade. After this transaction, Cox directly holds 370,834 shares, including 268,645 unvested RSUs, and also reports indirect holdings through trusts for the benefit of a child.
DYN filer submitted a Form 144 notice relating to proposed sales of Common Stock consisting of 11,250 Restricted Stock Units and disclosing a prior disposition of 2,732 shares on 03/05/2026. The filing lists 165,313,769 shares outstanding as of 05/13/2026.